TheraVet SA Logo

TheraVet SA

ALVET | BR

Overview

Corporate Details

ISIN(s):
BE0974387194
LEI:
984500804EBR3F1EFF71
Country:
Belgium
Address:
Avenue Jean Mermoz 32, 6041 Charleroi
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

TheraVet is a vet biotech company headquartered in Belgium (Jumet, Wallonia) with an US-based subsidiary. TheraVet's mission is to develop innovative, safe and effective treatments to improve the well-being and quality of life of companion animals suffering from osteoarticular diseases. TheraVet's main targets (indications & applications) are osteoarthritis, ligament & tendon injuries and bone surgery in cats and dogs as well as horses. TheraVet works in close collaboration with key opinion leaders in Belgium and abroad (France, Switzerland, United Kingdom & United States) to better address the ever-increasing needs of veterinary medicine.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-07 19:57
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 197.8 KB
2025-03-07 19:57
Legal Proceedings Report
Informations privilégiées / Autres communiqués
French 197.8 KB
2025-03-07 00:00
Legal Proceedings Report
20250307CA _EGEIRO CP eng.pdf
English 183.2 KB
2025-03-07 00:00
Legal Proceedings Report
20250307 CA_EGEIRO CP.pdf
French 187.0 KB
2025-01-27 00:00
M&A Activity
CP 20250127 EURONEXT qualification apport actif H4 acquisition inversée.pdf
French 644.6 KB
2025-01-27 00:00
Regulatory News Service
CP 20250127 EURONEXT qualification apport actif H4 acquisition inversée.pdf
French 644.6 KB
2024-12-12 18:00
Major Shareholding Notification
Informations privilégiées / Autres communiqués
French 193.7 KB
2024-12-12 00:00
Major Shareholding Notification
CP_EGEIRO-121224_notification_de_transparence_ARTICLE 14.pdf
French 193.7 KB
2024-12-05 18:00
Share Issue/Capital Change
Informations privilégiées / Autres communiqués
French 182.9 KB
2024-11-18 18:00
Board/Management Information
Inside Information / Other news releases
English 191.3 KB
2024-11-18 18:00
Board/Management Information
Informations privilégiées / Autres communiqués
French 165.7 KB
2024-11-18 00:00
Board/Management Information
EGEIRO-181124_CP démission EB.pdf
French 165.7 KB
2024-10-29 07:30
Post-Annual General Meeting Information
Inside Information / Other news releases
English 257.0 KB
2024-10-29 07:30
Post-Annual General Meeting Information
Informations privilégiées / Autres communiqués
French 287.8 KB
2024-10-28 07:30
Post-Annual General Meeting Information
CP_TheraVet_AG_FR.pdf
French 268.3 KB

Automate Your Workflow. Get a real-time feed of all TheraVet SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for TheraVet SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-11-21 Bastianelli Enrico Board Other 200,000 380,000.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.